TargetMol

AS-0141

Product Code:
 
TAR-T10728
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T10728-1mg1mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10728-5mg5mg£405.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10728-10mg10mg£567.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10728-25mg25mg£862.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10728-50mg50mg£1,139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10728-100mg100mg£1,508.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Cdc7-IN-6 is a potent Cdc7 kinase inhibitor (IC50=4 nM) extracted from patent WO2019165473A1(compound I- D) with anti-tumor activity.
CAS:
1402057-88-8
Formula:
C21H22F3N5O4
Molecular Weight:
465.433
Pathway:
Cell Cycle/Checkpoint
Purity:
0.98
SMILES:
CCOC(=O)C1=C(NN2CCN(CC(F)(F)F)CC2)OC(=C/c2c[nH]c3ncccc23)C1=O
Target:
CDK

References

Takayuki Irie, et al. Discovery of AS-0141, a Potent and Selective Inhibitor of CDC7 Kinase for the Treatment of Solid Cancers. J Med Chem. 2021 Oct 14;64(19):14153-14164. Christian Andrew HASSIG, et al. Methods of treatment of cancer comprising cdc7 inhibitors. WO2019165473A1.